Navigation Links
CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
Date:4/1/2008

lo(TM) catheter is well tolerated with a very low rate of the complications normally associated with stroke patients. In addition, the FDA has recently approved an expansion in the scope of the trial to now treat patients up to 14 hours after symptom onset.

Investigator Gary L. Bernardini, Director of the Stroke Service at Albany Medical Center who has enrolled a number of patients in the trial says, "We continue to be encouraged by the safety profile of the treatment and look forward to the completion of the pivotal trial as well as applying this technology to additional populations in future studies."

In addition to the SENTIS trial, CoAxia continues to enroll within two additional feasibility studies, one which applies NeuroFlo treatment to stroke patients up to 24 hours after symptom onset and another which adds NeuroFlo treatment to the current standard of care -- intravenous delivery of the thrombolytic drug, t-PA.

CoAxia, Inc. is a venture-backed, privately held, development-stage company focused on providing perfusion augmentation therapies that improve outcomes for patients with cerebral ischemia resulting from stroke, vasospasm and other conditions.


'/>"/>
SOURCE CoAxia, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...on for Targeted Therapies That Ensure...BEACH, Calif., and AMSTERDAM, Netherlands, Sept. 4...lar cancer diagnostics,today announced the launch...ows physicians to quantitatively determine the gen... progesterone receptor (PR) and Human Epidermal,gr...
(Date:9/3/2008)...arch and Education Foundation,s Within Our Reach ... Treating and Understanding RA...time during its,unprecedented initiative to find a...ge of Rheumatology Research and Education Foundati...arch funded by the Within Our,Reach: Finding a Cur...
(Date:9/3/2008)...edarone) decreased the risk of,stroke by 34% in pa...lready adequately treated by antithro...swire-FirstCall/ -- The results of a,post-hoc anal...ted today at,the clinical trial update session of ...in Munich, Germany. Previous results from the land...
(Date:9/3/2008)...rstCall/ -- A sub-analysis of,the TRITON-TIMI 38 c...,compared with clopidogrel significantly reduced t...cent vs. 9.7 percent, p<0.0001), regardless,of whe...ery-opening,procedure known as percutaneous corona...eously during the longer-term maintenance phase. T...
Breaking Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Protect Your Adolescents Against More Than Just A Cold This Winter 12551 1Protect Your Adolescents Against More Than Just A Cold This Winter 12551 2Prime Your Immune System During the Peak of Cold Season and Beyond 12548 1Prime Your Immune System During the Peak of Cold Season and Beyond 12548 2Americas 50 best hospitals 2008 released by HealthGrades 12545 1Americas 50 best hospitals 2008 released by HealthGrades 12545 2Americas 50 best hospitals 2008 released by HealthGrades 12545 3Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In Hospital Infections 12542 1Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In Hospital Infections 12542 2Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In Hospital Infections 12542 3Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In Hospital Infections 12542 4
...re-FirstCall/ -- Keryx,Biopharmaceuticals, Inc. to...) (sulodexide oral gelcap) have been selected for,...ions scheduled to,take place at the upcoming Ameri...fic Sessions and exposition at the McCormick Place... these abstracts, which highlight the mechanism of...
...Jun 21, 2007 - Advanced Cell,Technology, Inc. (OTC...nic stem cell (hESC) line without destroying an em...development was announced by,Robert Lanza, M.D., V...nced Cell Technology (ACT) on Tuesday at the fifth...tem Cell Research (ISSCR),in Cairns, Australia., I...
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois 2Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois 3Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois 4Advanced Cell Technology Develops First Human Embryonic Stem Cell,Line without Destroying an Embryo 2Advanced Cell Technology Develops First Human Embryonic Stem Cell,Line without Destroying an Embryo 3
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ith testicular cancer has increased significantly ...ch has now shown that fatherhood is a reachable po... Testicular cancer is the most common form of canc...tly more common on the right side than on the left...
...CG of the University of Iowa and colleagues at the...hat Gatorade and Pedialyte are equally effective a...m and vomiting related to acute viral gastroenteri...ed their findings at the 70th Annual Scientific Me...
...he American Association for Cancer Research (AACR)...rian food protects the host body from cancer occur...ting broccoli sprouts which is found to be effecti...to stomach and oral cancers. An other study has sh...
Avian flu-free India Considers Importing Vaccine
Other Medicine News:Health News:Testicular Cancer Patients Have Improved Reproductive Outcomes After Treatment 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: